Objectives
The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value. Methods
The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis. Results
In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's <i>q</i> was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (<i>t</i>–2 and <i>t</i>–5, respectively) were statistically significant (<i>p</i> < 0.1), whereas those of previous years 1, 3, and 4 years (<i>t</i>–1, <i>t</i>–3, and <i>t</i>–4, respectively) were not statistically significant. Conclusion
R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.
Citations
Citations to this article as recorded by
Entrepreneurial Orientation and Knowledge‐Driven Innovation Fahad Aljaeed, Nasser Alqahtani, Basma Khoja Knowledge and Process Management.2026; 33(3): 1095. CrossRef
Innovation Paradox and firm value in global Big Tech: Lag effects and the moderating role of profitability Young Wan Jin, Taeyeon Oh Journal of Open Innovation: Technology, Market, an.2026; 12(3): 100835. CrossRef
Finding the marketing sweet spot: when and where it works best Tarun Kumar Soni, Sanjeewani Sehgal, Divya Mehta Marketing Intelligence & Planning.2026; : 1. CrossRef
R&D investment and corporate total factor productivity under the heterogeneous environmental regulations: evidence from Chinese micro firms X. Ding, Y. Zhang, Y. Fu, Z. Xu International Journal of Environmental Science and.2025; 22(2): 753. CrossRef
Impact of Chinese environmental protection tax law on high-pollution firms' employment growth - A quasi natural experiment Yunshu Shao, Yuxiang Cheng Economic Analysis and Policy.2025; 86: 416. CrossRef
Exploration of R&D input and technological innovation output in high-tech industries—based on the perspective of financing channels of China Chengguo Jin, Faizal Baharum, Dayao Li, Md Azree Othuman Mydin, Ernawati Mustafa Kamal Sage Open.2025;[Epub] CrossRef
A new perspective for European SMEs’ innovative support analysis: Does non-financial support matter? Solomon Gyamfi, Wolfgang Gerstlberger, Viktor Prokop, Jan Stejskal Heliyon.2024; 10(1): e23796. CrossRef
Lead–lag effect of research between conference papers and journal papers in data mining Yue Huang, Runyu Tian WIREs Data Mining and Knowledge Discovery.2024;[Epub] CrossRef
R&D activity and firm performance: mapping the field Kseniia Boiko Management Review Quarterly.2022; 72(4): 1051. CrossRef
Pharmaceutical industry in export marketing: a closer look at competitiveness Mehdi Mohammadzadeh, Nima Bakhtiari, Reza Safarey, Tayebeh Ghari International Journal of Pharmaceutical and Health.2021; 13(3): 331. CrossRef
The effect of intangible assets on sustainable growth and firm value – Evidence on intellectual capital investment in companies listed on Bucharest Stock Exchange Catalin Ionita, Elena Dinu Kybernetes.2021; 50(10): 2823. CrossRef
AR-GE GİDERLERİ İLE KÂRLILIK VE BÜYÜME ARASINDA NEDENSELLİK İLİŞKİSİ: BIST ÜZERİNE BİR İNCELEME Mehmet DİKİCİ, Kadir GÜRDAL Muhasebe ve Vergi Uygulamaları Dergisi.2021; 14(3): 1193. CrossRef
R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry Chih-Yi Su, Yao-Ning Guo, Kuang-Cheng Chai, Wei-Wei Kong Frontiers in Public Health.2021;[Epub] CrossRef
R&D SPENDING AND FINANCIAL PERFORMANCE: AN INVESTIGATION IN AN EMERGING MARKET Nasıf ÖZKAN International Journal of Management Economics and .2021;[Epub] CrossRef
The persistence of current market valuation of future capital investment Nancy Beneda Journal of Corporate Accounting & Finance.2020; 31(3): 163. CrossRef
Sustainability assessment of universities as small-scale urban systems: A comparative analysis using Fisher Information and Data Envelopment Analysis Ning Ai, Marc Kjerland, Cynthia Klein-Banai, Thomas L. Theis Journal of Cleaner Production.2019; 212: 1357. CrossRef
Analysing future change in the EU's energy innovation system Yeong Jae Kim, Charlie Wilson Energy Strategy Reviews.2019; 24: 279. CrossRef
A review of three years' experience of the first pharmacometrics company in Korea So Jin Lee, Sangil Jeon Translational and Clinical Pharmacology.2019; 27(4): 149. CrossRef
The impact of inter-industry R&D technology spillover on carbon emission in China Jianling Jiao, Yufei Yang, Yu Bai Natural Hazards.2018; 91(3): 913. CrossRef
Characteristics of Corporate R&D Investment in Emerging Markets: Evidence from Manufacturing Industry in China and South Korea Jian Xu, Jae-Woo Sim Sustainability.2018; 10(9): 3002. CrossRef
R&D Investments, EPO Patent Applications and the Economic Heterogeneity within the EU Zuzana Potužáková, Jan Öhm Review of Economic Perspectives.2018; 18(2): 177. CrossRef
First
Prev
